SRP-9001 (Delandistrogene Moxeparvovec)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for SRP-9001 (Delandistrogene Moxeparvovec), covering 2025-11-20 to 2025-11-20. Get the full timeline:
Most recent: Clinical Trial Update: A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74) [Phase 1]